OTX1 Contributes to Hepatocellular Carcinoma Progression by Regulation of ERK/MAPK Pathway

Hua Li, Qian Miao, Chun-wei Xu, Jian-hui Huang, Yue-fen Zhou, and Mei-juan Wu

INTRODUCTION

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide and is globally the third leading cause of cancer-related deaths (1,2). The 5-year survival rate for patients suffering from HCC is only 7%, and few patients with symptomatic disease survive for > 1 year (3). Since traditional curative therapies, such as surgical resection, transplantation, or percutaneous ablation are only eligible for a minority of patients (4), our improving knowledge of hepatic carcinogenesis and the signaling pathways that control tumor growth and metastasis has led to the identification of several potential therapeutic targets. Numerous signaling pathways, such as extracellular signal regulated kinase/mitogen-activated protein kinase (ERK/MAPK), vascular endothelial growth factor receptor/endothelial growth factor receptor (VEGFR/EGFR), Wingless type (Wnt)/β-catenin, and PI3K/AKT/mTOR, have been suggested to be the potential targets (5,6). One example is the development of Sorafenib which is a tyrosine kinase inhibitor (TKI) that inhibits VEGFR, platelet-derived growth factor receptor (PDGFR), B-Raf, Fms-related tyrosine kinase (FLT), and c-kit (7,8). Results from large-scale phase III clinical trials have made Sorafenib the only approved molecular targeted drugs for HCC treatments. Thus, establishment of Sorafenib has driven the development of molecularly targeted therapies and unveiled a new direction for HCC treatments (6).

Orthodenticlehomebox 1 (OTX1) overexpression had previously been associated with the progression of several tumors. The present study aimed to determine the expression and role of OTX1 in human hepatocellular carcinoma (HCC). The expression level of OTX1 was examined by quantitative real-time PCR (qRT-PCR) in 10 samples of HCC and paired adjacent non-cancerous tissues, and by immunohistochemistry (IHC) analysis in 128 HCC samples and matched controls. The relationship between OTX1 expression and the clinicopathological features were also analyzed. Furthermore, the effects of OTX1 knockdown on cell proliferation and migration were determined in HCC cell lines. Axenograft mouse model was also established to investigate the role of OTX1 in HCC tumor growth. The qRT-PCR and IHC analyses revealed that OTX1 was significantly elevated in HCC tissues compared with the paired non-cancerous controls. Expression of OTX1 was positively correlated with nodal metastasis status (P = 0.009) and TNM staging (P = 0.001) in HCC tissues. In addition, knockdown of OTX1 by shRNA significantly inhibited the proliferation and migration, and induced cell cycle arrest in S phase in vitro. Tumor growth was markedly inhibited by OTX1 silencing in the xenograft. Moreover, OTX1 silencing was causative for the decreased phosphorylation level of ERK/MAPK signaling. In conclusion, OTX1 contributes to HCC progression possibly by regulation of ERK/MAPK pathway. OTX1 may be a novel target for molecular therapy towards HCC.

Keywords: OTX1; Hepatocellular Carcinoma; Growth; Migration; ERK/MAPK
in neural tumors, such as medulloblastomas (14), especially the specific nodular/desmoplasmic subtype (15). Further findings of the overexpression and cancer-promotion effects of OTX1 in breast cancer (16) and colorectal cancer (17) have collectively suggested that OTX1 might be widely implicated in the development and progression of human carcinogenesis.

In view of these findings, we sought to determine the expression of OTX1 in human HCC tissues, and explore the functional effects of OTX1 silencing on HCC progression in vitro and in vivo. The possible mechanisms that are involved in OTX1-related hepatic carcinogenesis will also be examined in this study.

MATERIALS AND METHODS

Cell lines and cell culture

Human HCC cell lines Hep G2 and SMMC-7221 were purchased from the Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Shanghai, China). Both cell lines were maintained in Rosewell Park Memorial Institute 1640 (RPMI-1640) medium (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS, Gibco). Culture medium was refreshed every two days. Cell culture was maintained in an incubator at 37°C in a humidified atmosphere with 5% CO₂.

Reagents

Primary antibodies against OTX1 and β-actin were purchased from Cell Signaling Technology (Boston, MA, USA). Antibodies against MEK, ERK, MAPK, and JNK and the corresponding antibodies against their phosphorylation were purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Antibodies against GAPDH and β-actin were purchased from Cell Signaling Technology (Boston, MA, USA). Antibodies against MEK, ERK, MAPK, and JNK and the corresponding antibodies against their phosphorylation were purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Antibodies against OTX1, β-actin and GAPDH were purchased from Cell Signaling Technology (Boston, MA, USA).

HCC tissues and immunohistochemistry (IHC) analysis

A total of 128 cases of human HCC and the paired adjacent non-cancerous tissues were collected. The clinicopathological information was provided for research purposes. Samples were paraffin-embedded and sliced. Slides were then subjected to deparaffinization/rehydration, followed by the antigen retrieval in a microwave at 100°C for 10 minutes in 0.1 mol/L citric acid buffer (PH 6.0). Slides were thereafter blocked by 5% skim milk for 1 hour at room temperature, and later incubated with the corresponding primary antibodies at 4°C overnight. After PBS washes, slides were incubated with secondary antibodies at room temperature for 1 hour. Signals for each slide were developed in pre-made 0.05% diaminobenzidine (DAB) containing 0.01% hydrogen peroxidise (H₂O₂). Slides were mounted for imaging under a light microscopy (Olympus, Japan).

Western blot analysis

Cells were harvested 48 hours after culture. The total protein was extracted and quantified using a BCA kit. An equal amount of 30 ng protein was loaded to each lane in a 12% SDS-PAGE gel. The gel was then transferred to a nitrocellulose (NC) membrane for 1.5 hours under a voltage of 100v. The membrane was preceded to antigen blocking with 5% skim milk for 1 hour, and incubated with primary antibody at 4°C overnight. After the overnight incubation with primary antibody, membrane was washed with TBST, and incubated with secondary antibody for 1 hour at room temperature. The immunoreactivity was detected with enhanced chemoluminescent autoradiography (ECL kit, Amsershaim, Pittsburgh, PA, USA) according to the manufacturer’s instruction. The β-actin was synchronously detected for loading control.

Quantitative real-time PCR (qRT-PCR)

Total RNA was extracted using Trizol solution (Invitrogen, Shanghai, China) and immediately reversely transcribed into cDNA using the PrimeScript RT Master Mix Perfect Real Time (TaKaRa, Shiga, Japan). The cDNA was then subjected to amplification in an ABI prism-7500 real-time system with the procedure described in a previous report (18). Primer sequences were as follows:

OTX1, forward: 5’-CTGCTCTTCCCTCAATCAATGG-3’; reverse: 5’-ACCCTGACTTTGCTGTGTTCC-3’; GAPDH, forward: 5’-TG CACCACCAAAGCTTGGC-3’; reverse: 5’-GGCATGGACACTG TGGTCATGAG-3’.

GAPDH gene was amplified as an internal control. qPCR products were detected with SYBR Green on BioRad Connet Real-Time PCR platform. Relative quantitation was analyzed by 2-ΔΔCT method.

Cell viability assay

The CCK-8 kit was used to assess cell viability in a consecutive of 5 days. Cells transfected with shOTX1 (shRNA group) or the negative control shRNA (NC group) were seeded in triplicate in a 96-well plate at an initial density of 4 × 10³/well. Cells without any transfection (control group) were also synchronously plated. Cell viability is reflected by cell numbers which depends on the absorbance after addition of 10 μL cck-8 solution into each well. Cells were further incubated for 2 hours after the addition of cck-8 in the incubator at 37°C. Subsequently, the absorbance value for each well was measured using a synergy 2 multi-mode microplate reader (Bio Tek Instruments, Winooski, VT, USA) at 450 nm. All experiments were repeated at least three times.

Colony formation assay

Hep G2 and SMMC-7221 cells were evenly seeded into 6-well plates, respectively, at an initial density of 1 × 10⁴ cells/well. Cells were then transfected with specific shOTX1 (shRNA group) or
the negative control shRNA (NC group) or without any transfection (control group) with lipofectamine 2000. After 48 hours growth, the supernatant was removed and cells were allowed to growth under normal conditions with the medium refreshed every two days. Ten days later, the cells from each group were allowed to form colonies and were fixed using 4% paraformaldehyde prior to staining with 0.1% crystal violet. After washing, the plates were air-dried, and stained colonies were photographed using a microscope (Leica, Wetzlar, Germany). Colonies were also counted and quantified.

**Cell cycle analysis**

After transfecting the cells with shOTX1 or scrambled shRNAs for 48 hours, the cells from each group were detached using trypsin, and re-suspended using the culture medium. Cells were then counted and a total of 1 × 10^6 cells were fixed with 70% (v/v) ethanol overnight at 4°C. After washing twice with PBS, the cells were then stained with a solution that contained 50 μg/mL of Prodim Iodide (PI) and 100 μg/mL RNase A for 30 minutes in the dark at room temperature. The stained cells were analyzed by flow cytometry (Beckman Coulter, Epics XL, Brea, CA, USA).

**Cell migration assay**

Briefly, 100 μL of Hep G2 and SMMC-7221 cells (9 × 10^4 for each) (48 hours post-transfection) in serum-free medium were placed into the upper chambers (8 μm pore size, Millipore) which were later placed into 24-well plates. Medium containing 10% FBS was added to the lower chamber. After incubation at 37°C for 12 hours, cells on the under- surface of the membrane were fixed with 4% paraformaldehyde, followed by 0.1% crystal violet staining for 30 minutes. Five random fields were photographed for each group of cells at 200 × magnification. The migrated cell numbers for each group were then counted and averaged from the five selected images. Each experiment was performed in triplicate.

**Mouse xenograft HCC models**

Twelve six-week-old female athymic nude mice (BALB/cnu/nu) were purchased from Chinese Academy of Sciences (Shanghai, China). Mice were randomized and equally assigned into the NC group or shRNA group (n = 6 for each group). A total of 1 × 10^6 Hep G2 cells were subcutaneously injected into the left flank of each mouse. Tumor diameters were periodically measured (twice a week) and tumor volumes (TV) were calculated using the formula TV = L × W^2/2 (L denotes the longer dimension, W denotes the smaller dimension). On day 25 after tumor cell injection, one mouse from the shRNA group sacrificed. By day 27, all mice were dislocated to death and the excised tumor tissues were weighed. All efforts were made to minimize suffering.

**Statistical analysis**

All data were expressed as the means ± standard error (SEM). An independent Student’s t-test was used to compare the difference between groups. A P value < 0.05 was considered of statistical significance. All statistical analyses were performed using SPSS 16.0 (SPSS Inc, Chicago, IL, USA).

**RESULTS**

**OTX1 is highly expressed in clinical HCC tissues**

To determine the expression level of OTX1 in human HCC tissues, we initially performed qRT-PCR analysis of OTX1 mRNA level in 10 samples from HCC and the paired adjacent tissues. The result showed that the average mRNA level in the tumor tissues were significantly higher than that in the adjacent tissues (P = 0.008). mRNA level of OTX1 in tumors were approximately two-fold increased compared with the non-cancerous tissues (Fig. 1A). The protein level of OTX1 was further assessed by IHC analysis in a subset of 128 cases of HCC tissues and the paired adjacent tissues. Expression of OTX1 was graded as negative (-), weakly positive (+), moderate positive (++), and strongly positive (++++) by experienced pathologists according to the stain density. Representative images showing the staining results of OTX1 in distinct tissues were presented in Fig. 1B. Our

---

**Fig. 1. OTX1 is highly expressed in clinical HCC tissues.**

(A) qRT-PCR analysis showed that the average mRNA level of OTX1 in the tumor tissues were approximately two-fold increased compared with the paired non-cancerous tissues (P = 0.008). (B) Protein level of OTX1 was analyzed by IHC in a subset of 128 cases of HCC tissues and the paired adjacent non-cancerous tissues. Staining result for each slide was graded as negative (-), weakly positive (+), moderate positive (++), and strongly positive (++++) according to the stain density. OTX1 was shown to be mainly located in the membrane and cytoplasm. The representative images that showed the markedly higher level of OTX1 in tumor tissues than non-cancerous tissues were provided. Magnification 400 ×.
results showed that the protein level of OTX1 was markedly higher in the tumor tissues than the non-cancerous tissues (Fig. 1B). While OTX1 was barely expressed in the normal tissues, it was intensely stained and showed to be mainly located in the membrane and cytoplasm (Fig. 1B). These results suggest that OTX1 is overexpressed in the HCC tissues at both mRNA and protein levels.

Expression of OTX1 is positively correlated with metastasis status and TNM staging

To determine whether expression of OTX1 was associated with the clinicopathological variables, we carried out Spearman correlation analysis to determine the association between OTX1 expression and the common clinicopathological parameters in the 128 cases of HCC tissues (Table 1). Statistics revealed that expression of OTX1 were not significantly different in tumor and non-cancerous tissues with respect to the onset age ($P = 0.070$), gender ($P = 0.856$), tumor size ($P = 0.642$), and tumor differentiation ($P = 0.613$). However, expression of OTX1 was observed to be positively correlated with the nodal metastasis ($P = 0.009$, $\chi^2 = 6.79$) and TNM staging ($P = 0.010$, $\chi^2 = 6.59$). These data indicate that expression of OTX1 in HCC may be associated with HCC progression, particularly with metastasis status and TNM staging.

Knockdown of OTX1 inhibits cell proliferation and colony formation in vitro

In light of the results above, we further investigated whether OTX1 played any functional role in HCC progression. To this end, we adopted shRNA against OTX1 (shOTX1) to knock down the expression of OTX1 in HCC cell lines Hep G2 and SMMC-7221. Effects of OTX1 knockdown on cell viability and colony formation were then assessed. Initially, the knockdown efficiency of shRNA was assessed (Fig. 2). The protein level of OTX1 was accordingly decreased after transfection of shOTX1 in both cell lines (Fig. 2C).

Table 1. Correlation between the expression of OTX1 and clinicopathological variables in hepatocellular carcinoma (n = 128)

| Variables          | Case No. | OTX1 expression | P value |
|--------------------|----------|-----------------|---------|
|                    |          | /+ | +++/++++ | (n = 43) | (n = 85) |
| Age (yr)           |          | 63 | 26 | 37 | 0.070 |
| ≤ 62               |          | 65 | 17 | 48 |
| > 62               |          | 63 | 26 | 37 |
| Gender             |          | 58 | 19 | 39 | 0.856 |
| Female             |          | 70 | 24 | 46 |
| Male               |          | 58 | 19 | 39 |
| Tumor size (cm)    |          | 30 | 10 | 20 | 0.881 |
| ≤ 2                |          | 51 | 16 | 35 |
| > 2                |          | 37 | 17 | 30 |
| Nodal metastasis   |          | 78 | 33 | 45 | 0.009* |
| Negative           |          | 50 | 10 | 40 |
| Positive           |          | 90 | 29 | 61 |
| Tumor differentiation |        | 38 | 14 | 24 |
| Well/moderate      |          | 38 | 14 | 24 |
| Poor               |          | 38 | 14 | 24 |
| TNM stage*         |          | 99 | 39 | 60 | 0.01* |
| I/II               |          | 99 | 39 | 60 |
| III/IV             |          | 29 | 4 | 25 |

*P < 0.05; **TNM staging is a classification of malignant tumor in which T describes the size of primary tumor, N describes nearby lymph nodes that are involved, and M describes distant metastasis.
in a consecutive of 5 days. It was observed that Hep G2 cells began to exhibit a slower proliferation rate since day 3. By day 5, the total cell numbers in shOTX1-transfected Hep G2 cells were only half of that in the control cells (Fig. 3A). Comparable results were also observed in the SMMC-7221 cells (Fig. 3B). Colony formation ability was also impaired after knockdown of shOTX1. Transfection of shOTX1 with Hep G2 cells and SMMC-7221 cells caused visually significantly fewer colonies in the plates (Fig. 4A). Quantification data showed that only average 30 colonies were formed in shOTX1-transfected Hep G2 cells (15% of the controls). About 50 colonies were formed in shOTX1-transfected SMMC-7221 cells, accounting for only 19% of the controls. *P < 0.01.

Knockdown of OTX1 induces cell cycle arrest in S phase
To explain the cell growth retardation by shOTX1, the flow cytometry was employed to analyze the cell cycle distribution. As shown in Fig. 5, the cell proportion in G0/G1 phase was similar among the three groups. However, cell proportion in S phase was significantly higher, whereas the proportion in G2/M phase was lower in both shOTX1-transfected Hep G2 cells and SMMC-7221 cells. In shOTX1-transfected Hep G2 cells, the cell percentage in S phase was approximately 28% relative to 21% for control cells. Accordingly, the cell percentage in G2/M phase was less than 2% relative to approximately 8% for control cells. This was also basically true in SMMC-7221 cells. It could be concluded that the cell growth retardation by shOTX1 was due to cell cycle arrest in S phase in both Hep G2 cells and SMMC-7221 cells.

Knockdown of OTX1 inhibits tumor growth in a xenograft mouse model
To assess the effects of OTX1 knockdown on hepatic tumor growth in vivo, Hep G2 cells that were transfected with shOTX1 in advance (shRNA group) were used to be subcutaneously injected to the left flank of each mouse. Negative control shRNA-transfected Hep G2 cells were synchronously injected as control (NC group). Tumor nodules were visible 8 days after injection and tumor dimensions were periodically monitored in both groups since then. Basically, tumor volumes in shRNA group were smaller than the control group, and were only 25% of it by day 27 when all mice from two groups were sacrificed (Fig. 6A). Tumor from each mouse was dissected (Fig. 6B) and weighed. The average weight of tumors from shRNA group was approximately 0.25 grams, whereas it was approximately 0.75 in the control group (Fig. 6C). Conclusively, the smaller volume in size and less weight in mass strongly suggest that knockdown of OTX1 in Hep G2 cells impaired the tumorigenic ability in vivo.

Fig. 3. Effects of OTX1 knockdown on cell viability. Knockdown of OTX1 by shRNA caused significantly lower proliferation rate in both Hep G2 cells (A) and SMMC-7221 cells (B). The proliferation rate was approximately half of the control cells by day 5. *P < 0.01.

Fig. 4. Knockdown of OTX1 impairs the colony formation ability in vitro. (A) Fewer colonies were visually observed in shOTX1-transfected Hep G2 cells and SMMC-7221 cells. (B) Quantification of the colony numbers showed that only average 30 colonies were formed in shOTX1-transfected Hep G2 cells (15% of the controls). About 50 colonies were formed in shOTX1-transfected SMMC-7221 cells, accounting for only 19% of the controls. *P < 0.01.
Knockdown of OTX1 contributes to hepatocellular carcinoma progression

Li H, et al. • OTX1 Contributes to Hepatocellular Carcinoma Progression

Fig. 5. Knockdown of OTX1 induces cell cycle arrest in S phase. Flow cytometry was employed to analyze the cell cycle distribution. Cell proportion in S phase was significantly increased, whereas cell proportion in G2/M phase was significantly decreased in shOTX1-transfected Hep G2 cells and SMMC-7721 cells.

* \( P < 0.01. \)

Fig. 6. Knockdown of OTX1 inhibits tumor growth in a xenograft mouse model. A mouse model bearing the hepatic cancer was initially established using shOTX1-transfected Hep G2 cells (shRNA group) or negative control shRNA-transfected Hep G2 cells (NC group). (A) Periodic monitor of tumor dimensions in both the NC group and shRNA group. Average tumor volume from shRNA group was only 25% of control group by day 27. (B) Tumors were dissected and presented on day 27. (C) All tumor weights were determined and averaged for each group. The average tumor weight from the shRNA group was approximately 33% of the control group.

* \( P < 0.05; \) ** \( P < 0.01. \)

Knockdown of OTX1 inhibits cell migration ability in vitro

Table 1 indicated that expression of OTX1 was positively correlated with nodal metastasis. Hence, we further examined the role of OTX1 in HCC cell migration. Both Hep G2 and SMMC-7721 cells were transfected with the specific shOTX1 (shRNA group) or with scrambled shRNA (NC group). Cells without any transfection were co-cultured. The staining with crystal violet showed that cells migrating to the under-surface of upper chamber were less in shRNA group than the control groups (Fig. 7A). After 12 hours, the under-surface of the upper chamber was stained with crystal violet. The stained cells were observed and photographed under a light microscopy. (B) Quantification of the migrated cell numbers showed that shOTX1-transfected cells exhibited significantly lower migration ability in both cell lines. Approximately 78% migration ability was decreased after knockdown of OTX1 in both Hep G2 and SMMC-7721 cells.

* \( P < 0.01. \)
Li H, et al. • OTX1 Contributes to Hepatocellular Carcinoma Progression

OTX1 Contributes to Hepatocellular Carcinoma Progression

http://jkms.org

Fig. 8. Deregulation of ERK/MAPK pathway is associated with knockdown of OTX1. Knockdown of OTX1 caused the according decreases of phosphorylated MEK, ERK, MAPK, and JNK without affecting the total MEK, ERK, MAPK, and JNK levels. ERK, extracellular signal regulated kinase; MAPK, mitogen-activated protein kinase; MEK, a MAPK kinase, also known as MAP2K, or dual-specificity mitogen-activated protein kinase kinase; JNK, c-Jun N-terminal kinase.

by shOTX1 by up to 78% after 12 hours culture in both Hep G2 and SMMC-7221 cells (Fig. 7B). These data confirm the relationship between expression of OTX1 and metastasis status, and suggest the critical role of OTX1 in HCC cell migration.

Deregulation of ERK/MAPK pathway is associated with silencing of OTX1

The ERK/MAPK pathway is constitutively expressed in HCC tissues (19), and closely associated with hepatic carcinogenesis and progression (20,21). The biological activity of ERK/MAPK pathway is activated by kinases which phosphorylate the cascade signaling. To assess whether the role of OTX1 in HCC was associated with the ERK/MAPK pathway, we detected the key components of ERK/MAPK pathway (ERK, MAPK, JNK, and MEK) and their phosphorylation levels. As shown in Fig. 8, phosphorylated MEK, ERK, MAPK, and JNK were consistently decreased after knockdown of OTX1 in both Hep G2 cells and SMMC-7221 cells. Knockdown of OTX1 had no effects on the expression level of total MEK, ERK, MAPK, and JNK. These results indicated that ERK/MAPK pathway was modulated by OTX1 in vitro.

DISCUSSION

Featured by rapid tumor growth, early vascular invasion, and high chemoresistance, HCC claimed approximately 600,000 deaths per year worldwide (22). In clinic, approximately 80% of HCC patients present with an advanced stage that is not amenable to surgical resection or liver transplantation (23). Recently, the multitkine inhibitor Sorafenib has been verified to have clinical benefits in advanced HCC patients due to its potent activity against VEGFR, PDGFR, B-RAF and c-kit et al. Treatment of Sorafenib prolonged the median survival time of HCC patients from 7.9 to 10.7 months in the randomized phase III clinical trial (24). This exiting result makes Sorafenib the only approved molecular targeted drug for HCC treatment and has largely facilitated the identification of novel molecules for the development of molecular targeted therapies.

OTX1 belongs to the homeobox (HB) gene and encodes transcription factors that have high-affinity binding to TAATCC⁄T elements on target genes (9). OTX1 was previously only implicated in the embryonic development, including brain regionalization, corticogenesis, organ sense, retina and normal mammary gland development (10,11,25). The recent findings of OTX1 in human carcinogenesis extended its normal function (13,15-17). OTX1 was considered one of the neuroectodermal markers previously (26), and has only been recently found re-expressed in breast cancer, colorectal cancer and specific type of medulloblastoma, indicating the potential role of OTX1 beyond neuroectodermal activity. In our study, it was observed that OTX1 was highly expressed in HCC tissues. Knockdown of OTX1 in Hep G2 and SMMC-7221 cells significantly caused cell growth retardation and induced cell cycle arrest in S phase. The in vivo tumorgenic ability was also impaired by knockdown of OTX1 in Hep G2 cells. Migration is a characteristic of malignant tumor. The blunted cell migration by knockdown of OTX1 strongly suggested that OTX1 was a critical contributor to HCC development and progression. These observations altogether concluded that OTX1 promoted HCC progression in vitro and in vivo.

HCC has a complicated molecular tumorigenesis in which MAPK pathway may be one of the major pathways (19,20). MAPKs, (also known as ERKs), act as an integration point for multiple biochemical signals, and are involved in a wide variety of cellular processes such as proliferation, differentiation, transcription regulation and development (27). The activation of this signaling requires its step-by-step phosphorylation by kinases. The mammalian MAPK family consists of ERK, p38, and c-Jun N-terminal kinase (JNK) with each of these enzymes consisting of at least three layers—an MAPK kinase kinase (also known as MAP3K, serine/threonine-specific protein kinase [RAF], and MEKK), an MAPK kinase (also known as MAP2K, dual-specificity mitogen-activated protein kinase kinase [MEK], and MKK), and an MAPK. The MAPK signaling is primarily involved in cell
growth and survival and regulates cell differentiation. This pathway has been widely implicated in the advanced stage HCC (28,29). The deregulation of MAPK signaling by silencing OTX1 in the present study would suggest a possible mechanism that OTX1 promotes HCC progression by regulation of MAPK signaling. Supporting evidence was that OTX1 induced cell cycle arrest in S phase and meanwhile modulated the MAPK pathway (Fig. 5 and 8). The close linkage between deregulation of MAPK pathway and cell cycle arrest is well recognized (particularly in S phase) (30-32), and would reinforce our hypothesis that the critical role of OTX1 in HCC is accomplished by modulation of the MAPK pathway. However, more work needs to be further done.

Identification of OTX1 as one potent mediator of HCC progression is of biological significance. Development of molecular therapy towards HCC has been progressing relatively slow regarding the approved drug(s). Management of HCC has been always calling for more work beyond Sorafenib (6). Our findings will hopefully provide novel clues for developments of molecular therapeutic strategies towards HCC. On the other hand, OTX1 was mainly implicated in the development (i.e. brain and retina) during embryogenesis. Its behavior has only been extended beyond the neuroectoderm recently. The identification of OTX1 as a mediator of tumor progression may advance our understanding of carcinogenesis.

In all, we studied the expression level and role of OTX1 in HCC. The critical role of OTX1 in HCC progression was examined in vitro and in vivo. In addition, OTX1 contributes to HCC progression possibly by regulation of ERK/MAPK pathway. The identification of OTX1 as a critical mediator of HCC progression may provide evidence for developments of novel molecular therapies towards HCC treatments.

**DISCLOSURE**

The authors have no potential conflicts of interest to disclose.

**AUTHOR CONTRIBUTION**

Study design: Xu CW, Wu MJ. Drafting of the manuscript: Li H, Miao Q, Wu MJ. Analysis and interpretation of data: Li H, Miao Q, Huang JH, Wu MJ. Laboratory data collection: Huang JH, Zhou YF. Statistical analysis: Xu CW. Clinical data collection: Li H, Miao Q, Huang JH, Zhou YF. Manuscript agreement: all authors.

**ORCID**

Hua Li http://orcid.org/0000-0003-1728-1622
Qian Miao http://orcid.org/0000-0002-1864-5697
Chun-wei Xu http://orcid.org/0000-0002-9021-6731
Jian-hui Huang http://orcid.org/0000-0002-2854-112X
Yue-fen Zhou http://orcid.org/0000-0002-0872-9782
Mei-juan Wu http://orcid.org/0000-0001-7893-2287

**REFERENCES**

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. *Gastroenterology* 2007; 132: 2557-76.
2. El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? *Hepatology* 2014; 60: 1767-75.
3. Bosch FX, Ribes J, Diaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. *Gastroenterology* 2004; 127: S5-16.
4. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. *Lancet* 2003; 362: 1907-17.
5. Shin JW, Chung YH. Molecular targeted therapy for hepatocellular carcinoma: current and future. *World J Gastroenterol* 2013; 19: 6144-55.
6. Chan SL, Mok T, Ma BB. Management of hepatocellular carcinoma: beyond sorafenib. *Curr Oncol Rep* 2012; 14: 257-66.
7. Wilhelm SM, Carter C, Tang L, Willke D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McGugh M, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. *Cancer Res* 2004; 64: 7099-109.
8. Chang YS, Adhane J, Trail PA, Levy J, Henderson A, Xue D, Bortolon E, Ichetovkin M, Chen C, McNabola A, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. *Cancer Chemother Pharmcol* 2007; 59: 561-74.
9. Klein WH, Li X. Function and evolution of Otx proteins. *Biochem Biophys Res Commun* 1999; 258: 229-33.
10. Acampora D, Postiglione MP, Avantaggiato V, Di Bonito M, Simeone A. The role of Otx and Otp genes in brain development. *Int J Dev Biol* 2000; 44: 669-77.
11. Larsen KB, Lutterodt M, Rath MF, Møller M. Expression of the homeobox genes PAX6, OTX2, and OTX1 in the early human fetal retina. *Int J Dev Neurosci* 2009; 27: 485-92.
12. Pagani IS, Terrinoni A, Marenghi L, Zucchi I, Chiaravalli AM, Serra V, Rovelli F, Sirchia S, Dionigi G, Mizioz M, et al. The mammary gland and the homeobox gene Otx1. *Breast* 2010; 16 Suppl 1: S33-6.
13. Omodei D, Acampora D, Russo F, De Filippi R, Severino V, Di Francia R, Frigeri E, Mancuso P, De Chiara A, Pinto A, et al. Expression of the brain transcription factor OTX1 occurs in a subset of normal germinal-center B cells and in aggressive Non-Hodgkin Lymphoma. *Am J Pathol* 2009; 175: 2609-17.
14. Zakrzewska M, Grešner SM, Zakrzewski K, Zalewska-Szewczyk B, Liber S, Dionigi G, Mizioz M, Frattini A, et al. OTX1 expression in breast cancer is regulated by p53. *Oncogene* 2011; 30: 3096-103.
17. Yu K, Cai XY, Li Q, Yang ZB, Xiong W, Shen T, Wang WY, Li YE. OTX1 promotes colorectal cancer progression through epithelial-mesenchymal transition. *Biochem Biophys Res Commun* 2014; 444: 1-5.

18. Li LL, Xue AM, Li BX, Shen YW, Li YH, Luo CL, Zhang MC, Jiang JQ, Xu ZD, Xie JH, et al. JMD2A contributes to breast cancer progression through transcriptional repression of the tumor suppressor ARHI. *Breast Cancer Res* 2014; 16: R56.

19. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. *Oncogene* 2010; 29: 4989-5005.

20. Wang S, Huang X, Li Y, Lao H, Zhang Y, Dong H, Xu W, Li JL, Li M. RN181 suppresses hepatocellular carcinoma growth by inhibition of the ERK/MAPK pathway. *Hepatology* 2011; 53: 1932-42.

21. Pratilas CA, Solit DB. Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. *Clin Cancer Res* 2010; 16: 3329-34.

22. Villanueva A, Minguez B, Forner A, Reig M, Llovet JM. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. *Annu Rev Med* 2010; 61: 317-28.

23. Thomas MB, Abbruzzese JL. Opportunities for targeted therapies in hepatocellular carcinoma. *J Clin Oncol* 2005; 23: 8093-108.

24. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* 2008; 359: 378-90.

25. Chen H, Sukumar S. Role of homeobox genes in normal mammary gland development and breast tumorigenesis. *J Mammary Gland Biol Neoplasia* 2003; 8: 159-75.

26. Jeon K, Lim H, Kim JH, Han D, Lee ER, Yang GM, Song MK, Kim JH, Cho SG. Bax inhibitor-1 enhances survival and neuronal differentiation of embryonic stem cells via differential regulation of mitogen-activated protein kinases activities. *Biochim Biophys Acta* 2012; 1823: 2190-200.

27. Burotto M, Chiu VL, Lee JM, Kohn EC. The MAPK pathway across different malignancies: a new perspective. *Cancer* 2014; 120: 3446-56.

28. Huynh H, Nguyen TT, Chow KH, Tan PH, Soo KC, Tran E. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. *BMC Gastroenterol* 2003; 3: 19.

29. Ito Y, Sasaki Y, Horimoto M, Wada S, Tanaka Y, Kasahara A, Ueki T, Hirano T, Yamamoto H, Fujimoto J, et al. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. *Hepatology* 1998; 27: 951-8.

30. Sun Y, Tang S, Jin X, Zhang C, Zhao W, Xiao X. Opposite effects of JNK and p38 MAPK signaling pathways on furazolidone-stimulated S phase cell cycle arrest of human hepatoblastoma cell line. *Mutat Res* 2013; 755: 24-9.

31. Sun Y, Tang S, Jin X, Zhang C, Zhao W, Xiao X. Involvement of the p38 MAPK signaling pathway in S-phase cell-cycle arrest induced by Furazolidone in human hepatoma G2 cells. *J Appl Toxicol* 2013; 33: 1500-5.

32. Iguchi T, Miyakawa Y, Yamamoto K, Kizaki M, Ikeda Y. Nitrogen-containing bisphosphonates induce S-phase cell-cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway. *Cell Signal* 2003; 15: 719-27.